Niagen Bioscience Inc (NAGE) — Financial statements
Income statement, balance sheet, and cash flow for Niagen Bioscience Inc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 129↑29.9% | 100↑19.2% | 84↑16.0% | 72↑6.8% | 67 | |
| Cost of Revenue | 46↑21.6% | 38↑15.9% | 33↑12.1% | 29↑12.7% | 26 | |
| Gross Profit | 83↑35.1% | 62↑21.3% | 51↑18.7% | 43↑3.2% | 41 | |
| Operating Expenses | ||||||
| R&D Expenses | 6↑5.2% | 6↑21.3% | 5↑2.7% | 5↑25.9% | 4 | |
| General & Administrative Expenses | 0.00↓100.0% | 18↓26.4% | 25↓11.7% | 28↓22.2% | 36 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 29↑11.5% | 26↓6.6% | 28↓0.1% | 28 | |
| SG&A Expenses | 63↑30.8% | 48↓7.0% | 51↓9.1% | 57↓12.6% | 65 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 69↑27.9% | 54↓4.5% | 56↓8.2% | 61↓10.4% | 69 | |
| Total Costs & Expenses | 115↑25.3% | 92↑3.0% | 89↓1.7% | 91↓4.1% | 95 | |
| Operating Results | ||||||
| Operating Income | 14↑85.0% | 8↑238.0% | -6↑69.9% | -19↑31.2% | -27 | |
| Depreciation & Amortization | 1↓2.3% | 1↓13.0% | 2↓9.5% | 2↑15.9% | 2 | |
| EBITDA | 16↑71.0% | 9↑336.5% | -4↑76.7% | -17↑34.2% | -25 | |
| EBIT | 14↑85.0% | 8↑238.0% | -6↑69.9% | -19↑31.2% | -27 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑88.4% | 1↑70.8% | 0.66↑21933.3% | 0.00↑105.5% | -0.06 | |
| Interest Income | 2↑88.4% | 1↑70.8% | 0.66↑21933.3% | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.06 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 4↑245.1% | 1↑70.8% | 0.66↓68.3% | 2↑3896.4% | -0.06 | |
| Income Before Tax | 18↑105.4% | 9↑279.3% | -5↑70.1% | -17↑39.0% | -27 | |
| Income Tax Expense | 0.81↑165.6% | 0.31 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 17↑103.3% | 9↑273.1% | -5↑70.1% | -17↑39.0% | -27 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 17↑103.3% | 9↑273.1% | -5↑70.1% | -17↑39.0% | -27 | |
| Bottom-Line Net Income | 17↑103.3% | 9↑273.1% | -5↑70.1% | -17↑39.0% | -27 | |
| EPS (Basic) | 0.22↑120.0% | 0.10↑242.9% | -0.07↑70.8% | -0.24↑40.0% | -0.40 | |
| EPS (Diluted) | 0.20↑81.8% | 0.11↑266.9% | -0.07↑72.5% | -0.24↑40.0% | -0.40 | |
| Weighted Average Shares | 79↓7.3% | 85↑21.1% | 71↑2.4% | 69↑2.6% | 67 | |
| Weighted Average Diluted Shares | 85↑7.2% | 80↑6.3% | 75↑7.5% | 70↑3.8% | 67 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.